Concomitant use of tacrolimus and voriconazole, both competitive inhibitors of the CYP450 3A4 isoenzyme, requires tacrolimus dose reduction. On the basis of clinical observations, we developed a preemptive dose-reduction strategy in allograft recipients who received voriconazole to maintain tacrolimus concentrations within a target range. A total of 27 patients started i.v. tacrolimus at an average daily dose of 0.022 mg/kg on day À1 (30% lesser than the usual starting dose). The dose was reduced by 30-40% if the 48-h steady-state concentration was 7-10 ng/ml, and by 40-50% if it was 10-15 ng/ml. No change was made if the concentration was o7 ng/ml. Subsequently, concentrations were generally monitored 2-3 times a week with dose adjustments as necessary. None of the 170 levels (3-12 per patient; median 5) obtained between days þ 1 and þ 16 were subtherapeutic (o5 ng/ml) and only 34 levels (20%) were 415 ng/ml. Each patient required dose reduction at least twice. The dose had to be increased in only two patients after the initial dose reduction. The median tacrolimus doses in mg/kg declined with time; being 0.022, 0.008 and 0.006 on days 0, 7 and 14, respectively. We conclude that a preemptive dose-reduction strategy is effective in maintaining tacrolimus concentrations within the desired therapeutic range, although serial monitoring remains prudent.
Introduction
Tacrolimus is widely used for the prevention of GVHD after allogeneic hematopoietic SCT(HSCT).
1,2 Adverse events such as renal and hepatic toxicity have been associated with increased tacrolimus blood concentrations after HSCT. 3, 4 Such adverse reactions may be preventable with therapeutic drug monitoring and coordinated dose adjustments.
Tacrolimus is primarily metabolized by the cytochrome P450 3A4 isoenzyme system. In addition, tacrolimus is also highly metabolized by CYP3A5. 5 The peri-transplant period is characterized by the administration of numerous drugs that can affect the cytochrome P450 system and alter tacrolimus clearance. Population pharmacokinetic studies in HSCT recipients have shown that liver or kidney impairment can result in decreased tacrolimus clearance and increased blood tacrolimus concentrations. 6 Invasive fungal infections are a source of considerable morbidity and mortality after HSCT. Voriconazole is a triazole drug with a broad spectrum of activity, and is one of the agents used for fungal prophylaxis after allogeneic HSCT. 7, 8 Voriconazole is a competitive inhibitor for the cytochrome P450 3A4, 2C9 and 2C19 isosenzyme systems. 9, 10 Predictably, numerous serious drug interactions have been described for voriconazole when combined with other drugs metabolized through these systems, including tacrolimus. 11, 12 As reported by others, 12 we observed increased tacrolimus blood concentrations when this agent was administered concomitantly with voriconazole. Bringing the concentration back within the target range required significant dose reduction multiple times. From clinical observations, we empirically developed a preemptive, twostep dose-reduction strategy for clinical use. In this report, we evaluate the success of this preemptive dose-reduction strategy in adjusting serial tacrolimus blood concentration levels in 27 patients after HSCT.
Patients and methods
A retrospective cohort analysis was completed for patients receiving voriconazole and tacrolimus according to the preemptive dose-reduction strategy. When voriconazole was initiated orally (200 mg twice daily from day 0 onwards), we clinically observed that multiple adjustments were required for tacrolimus as blood tacrolimus concentrations continued to increase for several days in the absence of dose changes for voriconazole. On the basis of the pattern of dose adjustments made, we developed the following tacrolimus dose-adjustment algorithm:
Patients expected to receive concomitant voriconazole began i.v. tacrolimus therapy at the daily dose of 0.022 mg/kg on day À1 by continuous infusion for more than 24 h. This represents a 30% dose reduction compared with the recommended starting dose of 0.03 mg/kg, 13 and is consistent with current product guidelines for reduction of tacrolimus dose when administered concomitantly with voriconazole. 12 Tacrolimus blood concentrations were serially monitored while patients were receiving i.v. tacrolimus. Quantitation of blood tacrolimus concentrations was completed in-house using an Abbott immunoassay (Abbott Laboratories, Abbott Park, IL, USA) as described previously. 14 Patients received a single 100 mg dose of hydrocortisone before stem cell infusion on day 0. The first tacrolimus blood concentration was drawn 48 h after the initiation of therapy. A minimum of three tacrolimus blood concentrations per patient was required for inclusion. According to hospital protocol, voriconazole 200 mg orally twice daily was initiated on day 0 of HSCT and was continued until a month beyond cessation of all immunosuppression as prophylaxis against invasive fungal infections. A second dose reduction of 30-40% was used if the 48-h steady-state blood concentration (day þ 1) was between 7 and 10 ng/ml, and of 40-50% if the blood concentration was between 10 and 15 ng/ml. No change was made if the blood concentration was o7 ng/ml. Tacrolimus dose was adjusted for a target range ¼ 5-15 ng/ml. Subsequently, blood concentrations were monitored 2-3 times a week with tacrolimus dose adjustments used as clinically necessary.
Blood chemistry including serum creatinine and bilirubin levels was also serially monitored. Tacrolimus dose changes in this study were based on tacrolimus blood levels. In accordance with standard clinical practice, a clinical pharmacist monitored all patient profiles to ensure patients did not receive any other drugs that might interact with tacrolimus and/or voriconazole. All patients were monitored by clinical pharmacists for other interacting medications. Medications were considered interactive if a warning existed in the package insert or tertiary reference at the time of medication dosing. 12, 15, 16 The data were collected for a total of 16 days. This retrospective review was approved by the Northwestern institutional review board and exempted by the Midwestern University Review Board.
A total of 27 consecutive allogeneic HSCT patients fulfilling the following criteria were studied: hematological malignancy, BU-fludarabine or melphalan ± CY conditioning, i.v. tacrolimus for GVHD prophylaxis from the beginning of immunosuppression, concomitant oral voriconazole at the dose of 200 mg twice a day, at least three available tacrolimus blood concentrations including one drawn 48 h after starting tacrolimus and preemptive tacrolimus dose adjustment.
Statistical analysis was performed using Intercooled Stata, version 10.1 (Statacorp, College Station, TX, USA). The Pearson correlation coefficient was used to assess for a possible correlation between variables. Simple linear regression was used to assess linear relationships. All tests were two-tailed, and P-values of o0.05 were considered statistically significant.
Results
A total of 170 tacrolimus blood concentration results were obtained from 27 patients. Patient characteristics are shown in Table 1 .
Absolute tacrolimus doses in mg (median, range) on days 0, 7 and 14 were 1.6 (1-2), 0.6 (0.13-1.4) and 0.4 (0.13-1.1), respectively. Doses standardized for weights (median, range) were 0.022 mg/kg (0.018-0.025), 0.008 mg/kg (0.004-0.022) and 0.006 mg/kg (0.004-0.017), respectively. Figures 1a and b depict the reduction in tacrolimus doses temporally from baseline to the end of the study period required to maintain blood concentrations in the given target range. Total daily absolute dose and dose in mg/kg generally decreased over the study period. Doses were ultimately reduced between 60 and 80% on a mg/kg basis compared with baseline dosing.
Mean tacrolimus blood concentrations decreased slightly as a function of time (P ¼ 0.135) (Figure 2 ), but were relatively stable within the therapeutic range over the study period: no level was subtherapeutic (o5 ng/ml) and B20% of them (n ¼ 33) were high (415 ng/ml) occurring early in the course of therapy (median day þ 5). An increase in the dose was required in only two patients after the initial dose reduction. As expected, the absolute tacrolimus dose correlated strongly (r ¼ 0.912; Po0.0001) with the weight-adjusted dose (mg/kg), Figure 3 .
No other significant drug interactions in patients taking ancillary medication were received during the HSCT Table 1 Baseline patient demographics
Age years, median (range) 55 (28-64) Wt, kg (range) 75 (50-100)
Transplant type Related donor (n, %) 4 (15%) Unrelated donor (n, %) 23 (85%)
Conditioning regimen BU/fludarabine (n, %) 16 (59%) Melphalan ± CY (n, %) 11 (41%)
Medical diagnosis AML (n, %) 14 (52%) NHL (n, %) 7 (26%) CLL (n, %) 2 (7%) Other (n, %) 4 (15%)
Abbreviation: NHL ¼ Non-Hodgkin's lymphoma.
period. There were no clinically significant changes in either the median serum creatinine levels (0.8 vs 0.8 mg/dl) or the median serum bilirubin levels (0.8 vs 0.9 mg/dl) when baseline values were compared with the end of therapy values, respectively.
Discussion
We found that the tacrolimus-voriconazole interaction can be anticipated, and preemptive dose-reduction strategies can help maintain tacrolimus concentrations in the target therapeutic range. Specifically, a dosage decrease of 30% on day À1, followed by an additional decrease of 40-50% (60-80% total decrease), ensured an appropriate decrease in blood tacrolimus concentrations to a value within the therapeutic range for most patients. Additional dosage reductions were required after preemptive dosage reduction, but seemed to be manageable as patients were generally already in the therapeutic window.
Tacrolimus is used extensively in HSCT recipients for the prevention of GVHD, and is the agent of choice for half the North American centers surveyed (ST; personal communication and unpublished data). Although the desired target blood tacrolimus level ranges varied, the most commonly used range was 5-15 ng/ml.
Maintaining blood tacrolimus concentrations within a narrow target range can be challenging in HSCT patients. Tacrolimus is primarily metabolized through the cytochrome P450 3A4 and cytochrome P450 3A5 isoenzyme systems, which exhibit 20-fold interpatient variability in metabolic activity. In addition, tacrolimus is also a substrate and inhibitor of the active drug transporter P-glycoprotein. In addition to a number of disease-and patient-specific factors that have been associated with changes in tacrolimus disposition, recipients of HSCT can potentially receive several drugs that may inhibit or induce the CYP450 system and can drastically change tacrolimus blood concentrations. Among these, the members of the triazole family of antifungal drugs (namely fluconazole, itraconazole and voriconazole) are routinely used around the HSCT period. The magnitude and clinical significance of the drug interactions between azoles and tacrolimus have been recently reviewed. 11 Differences in the inhibitory potency of the azole drugs on cytochrome P450 vary significantly (ketoconazole4itraconazole4voriconazole4 fluconazole). Earlier pharmacokinetic studies (PK) with tacrolimus in combination with fluconazole or itraconazole have measured tacrolimus blood concentrations when administered concomitantly with a triazole. Often, blood tacrolimus concentrations increased beyond the target range. In a small prospective study in which fluconazole 400 mg daily was used in combination with tacrolimus in HSCT recipients, tacrolimus levels increased by 16% and tacrolimus clearance decreased by 16%. 17 A study in renal allograft recipients reported that tacrolimus patients with the CYP 3A5 3/*1 genotype (expressers) were less susceptible to fluconazole inhibition than CYP3A5*5 nonexpressers, suggesting that the magnitude of the azole-tacrolimus interaction could, in part, be explained by CYP3A expression. 18 In a prospective study in which tacrolimus was used in combination with itraconazole in HSCT recipients, tacrolimus levels were increased by a median 85%. 19 The effects of coadministration of voriconazole and tacrolimus were first described in a liver transplant recipient. Increased blood levels of tacrolimus (10-fold) and in vitro inhibition of human microsomes (50%) at clinically relevant voriconazole concentrations was reported. 20 The package insert recommends reducing tacrolimus to 1/3 and monitoring drug levels. 12 Instead of letting tacrolimus levels exceed the target range, we preemptively decreased the initial tacrolimus dose (30%) and anticipated additional drug accumulation as tacrolimus blood concentrations reached a new steady state. Therefore, a second fixed dose reduction (40-50%) was initiated while tacrolimus blood concentrations were still within the target range. With these modifications, tacrolimus blood concentrations were maintained at desired concentrations. The results of this study concur with data collected from healthy individuals and suggest that significant increases in tacrolimus blood concentrations occur with coadministration of voriconazole, requiring significant dose reduction. Ultimately, dose reductions (median of 77% reduction from our baseline dose) were adequate to maintain tacrolimus blood concentrations within a target range.
Our results differ from a recently published article on voriconazole-tacrolimus interaction in HSCT recipients. In that study, measurement of baseline tacrolimus concentrations, followed by serial drug blood concentrations after the addition of voriconazole resulted in median tacrolimus blood concentrations, that is, 115% (25-308%) above the target range. 21 This study shows the large interpatient variability of the interaction and demonstrates the need for continued monitoring. It is important to note that a preemptive dose-reduction strategy was not used in their study. The magnitude of the effect of the tacrolimusvoriconazole interaction and the amount of tacrolimus interpatient variability differed significantly from our data as well. Differences in the results of these two studies may have been because of differences in the route of administration of tacrolimus (oral vs i.v.), the number of days after HSCT (day 106 vs day 0), the number of patients enrolled (11 vs 27), or the proportion of patients that may have been homozygous poor metabolizers (cytochrome P450 2C19). The authors concluded that tacrolimus dose adjustment could not be predetermined uniformly, but rather needed to be dosed empirically on an individual basis only. By contrast, our results suggest that initiating the stepwise preemptive tacrolimus dose reduction can be successful in maintaining initial tacrolimus blood concentrations within the target range for a majority of patients. However, serial monitoring is still essential. With this strategy, 495% of the individual mean tacrolimus blood concentrations were between 5 and 20 ng/ml, and 480% were between 5 and 15 ng/ml.
It seems reasonable to suggest that lack of preemptive dose reduction likely would have resulted in tacrolimus blood concentrations increasing steadily; however, we did not conduct a randomized study. Indeed, this analysis represents a retrospective validation of a clinical practice Tacrolimus (mg) Figure 3 Comparison of dose according to mg and mg/kg.
adopted on the basis of observations. Ensuring that tacrolimus blood concentrations remained within a relatively narrow therapeutic range most of the time may also have been effective in reducing toxicity as seen by unchanged serum creatinine and bilirubin levels. The results of this study need to be tested prospectively.
In conclusion, a preemptive two-step dose-reduction strategy (median of 77% total reduction from baseline) seems to result in tacrolimus blood concentrations within the target range for HSCT patients concomitantly receiving voriconazole. However, continued dose reductions are necessary and routine serial monitoring of blood concentrations is prudent as interpatient variability exists.
